Assessment of sVEGFR-1 concentration in patients with breast cancer;Ocena stȩżenia rozpuszczalnego receptora sVEGFR-1 u chorych na raka gruczołu piersiowego

Wspolczesna Onkologia

Volumn 14, Issue 3, 2010, Pages 189-195

  Thielemann, Anna ^a   Kopczyński, Zygmunt ^a   Baszczuk, Aleksandra ^a   Ćwiklińska, Karolina ^a   Grodecka Gazdecka, Sylwia ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Angiogenesis; Breast cancer; Receptor sVEGFR 1; VEGF

Indexed keywords

SOLUBLE VASCULOTROPIN RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER PATIENT; CANCER SIZE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIMARY TUMOR; SURGICAL TECHNIQUE; UNIVERSITY HOSPITAL;

EID: 77954356740     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: 10.5114/wo.2010.14128     Document Type: Article

References (32)

1. Folkmann J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536-42.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-93.
3. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23: 1782-90.
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev 2002; 2: 795-803.
5. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004; 6: 109-18.
6. Ferrara N, Gerger HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
7. Breier G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin Thromb Hemost 2000; 26: 553-9.
8. Charnock-Jones DS. Vascular endothelial growth factors (VEGFS), their receptors and their inhibition. Cell Transmissions. SIGMA 2005; 21: 2-6.
9. Wu H, Li Y, Zhu G, Zhang L, Zhang X, He X. Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma. Zhonghua Yi Xue Za Zhi 2002; 82: 708-11.
10. Carmeliet Peter. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptor. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
12. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M, Saito Y. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000; 77: 413-8. (Pubitemid 30368560)
13. Horing C, Weich HA. Soluble VEGF receptors. Angiogenesis 1999; 3: 33-9.
14. Barleon B, Reusch P, Totzke F, et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143-54. (Pubitemid 34032700)
15. Bussolati B, Dunk C, Grohman M. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001; 159, 3: 993-1008. (Pubitemid 32847190)
16. Wypych Agata, Zejda Jan E. Potrzeba badań przesiewowych raka piersi w Polsce. Medycyna Środowiskowa 2005; 8: 47-52.
17. Kozaczka A, Woszczyk D, Najda J. Mechanizmy kontroli angiogenezy oraz ich wykorzystanie kliniczne w zaawansowanych przypadkach raka jelita grubego. Współcz Onkol 2004; 8: 373-8.
18. Dvorak HF. Vascularpermeability factor/vascular endothelial growth factor a critical cytokine in tumor angiogenesis and potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
19. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR. Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 2003; 29: 497-50.
20. Enjoji M, Nakamuta M, Yamaguchi K, et al. Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma. World J Gastroenterol 2005; 11: 1167-71. (Pubitemid 40353003)
21. Savropoulus NE, Bouropoulos C, Ioachim I E. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004; 36: 45-48.
22. Świdzińska E, Ossolińska M, Naumnik W, Iżycki T, Kucejko W, Chyczewska E. Naczyniowo-śródbłonkowy czynnik wzrostu - VEGF i rozpuszczalny receptor - sVEGFR-1 w surowicy chorych na raka płuca. Pneumonol Alergol Pol 2004; 72: 389-94.
23. Thielemann A, Kopczyński Z, Grodecka-Gazdecka S, Piekarska B. Ocena stȩżenia naczyniowo-śródbłonkowego czynnika wzrostu (VEGF) u chorych na raka gruczołu piersiowego. Diagn Lab 2005; 41: 154-64.
24. Dales JP, Garcia S, Bonnie P. Prognostic significance of VEGF receptors, VEGFR-1 and VEGFr-2 in brest carcinoma.ANN Pathol 2003; 23: 297-305.
25. Korzeniewska M, Kołomecki K, Stȩpień H, Naze M, Stȩpié T, Kuzdak K. Ocena stȩżeń wybranych czynników pro- i antyangiogennych we krwi u chorych z nieczynnymi hormonalnie guzami nadnerczy. Endokrynol Pol 2005; 56: 39-44.
26. Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002; 22: 1877-80. (Pubitemid 34839213)
27. Toi M, Bando H, Ogawa T. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-8. (Pubitemid 34113411)
28. Belgore FM, Lip GY, Bareford D. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Hematol 2001; 66: 59-61. (Pubitemid 32006326)
29. Wierzbowska A, Robak T, Wrzesień-Kuś A, Krawczyńska A, Lech-Marańda E, Urbańska-Ryś H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149-53. (Pubitemid 37249233)
30. Bednarek W, Barczyński B, Kotarski J. Wartość prognostyczna sVEGFR-1 w przewidywaniu oporności na cisplatynȩ i paclitaksel u chorych na raka jajnika. Prz Menopauz 2005; 5: 65-71. (Pubitemid 43224311)
31. Myśliwiec P, Piotrowski Z, Zalewski B. Plasma VEGF-A and its soluble receptor R1 correlate with the clinical stage of colorectal cancer. Rocznik Akademii Medycznej w Białymstoku 2004; 49 suppl. 1: 85-7.
32. Opolski A, Wietrzyk J. Inhibitory neoangiogenezy w terapii przeciwnowotworowej. Post Hig Med Dośw 2001; 55: 369-85.